Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective randomized trial. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: A phase II study Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus--a prospective randomized trial. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. Clinical outcomes of mild hyperthermia for locally advanced rectal cancer treated with preoperative radiochemotherapy Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Intracavity hyperthermia in nasopharyngeal cancer: A phase III clinical study Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: Randomized controlled study Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. [Application of hyperthermic intraoperative intraperitoneal chemotherapy in patients with gastric cancer].
From 1990 to 1991 , 40 patients with squamous cell carcinoma of the thoracic oesophagus were admitted to our institutions and  chemotherapy ( oil Bleomycin p.o . and CDDP d.i.v . ) either combined with or without hyperthermia was performed , in a prospect i ve r and omized trial carried out to investigate the effects of hyperthermia . The two groups ( group A , consisting of 20 patients given chemotherapy alone ; and group B , made up of 20 given chemotherapy with hyperthermia ) were comparable with regard to various prognostic factors . Following the above treatment regimens , an oesophagectomy was done in 16 and 17 patients from groups A and B , respectively . A subjective improvement of dysphagia was seen in 8 ( 40.0 % ) , and in 14 patients ( 70.0 % ) , while a radiographic improvement was recognized in 5 ( 25.0 % ) and 10 cases ( 50.0 % ) in groups A and B , respectively . In the resected specimen of 16 ( group A ) and 17 patients ( group B ) , histopathological evidence of the effectiveness of the treatments were recognized in 3 ( 18.8 % ) and 7 ( 41.2 % ) from groups A and B , respectively . Excluding the cases of superficial carcinoma ( T1 tumour ) , histologic effectiveness of the treatments were recognized in 2 ( 14.3 % ) and 7 ( 58.3 % ) in groups A and B , respectively ( p < 0.05 ) . There was no difference in the occurrence of side effects between the groups . Therefore , the clinical and pathological effects were favourable in the hyperthermia combined with chemotherapy group , especially in the cases with advanced oesophageal cancer OBJECTIVE To evaluate the effects of continuous hyperthermic peritoneal perfusion ( CHPP ) together with st and ard chemotherapy on the prognosis of patients with gastric cancer invading the serosa . DESIGN Retrospective study . SETTING University hospital , Japan . SUBJECTS 174 patients who had undergone curative resection for gastric cancer invading the serosa ( T3 ) between 1980 and 1989 , 78 of whom had been r and omised to be treated with CHPP after operation and 96 who received st and ard chemotherapy .  INTERVENTIONS CHPP was done immediately after operation ; 8 - 10 l fluid containing 80 - 100 mg/m2 mitomycin C was perfused at a rate of 100 - 200 ml/minute , and inflow and out flow temperatures were maintained at 44 - 45 degrees C and 40 - 42 degrees C , respectively . This was followed by a st and ard regimen of mitomycin C and 1-(2-tetrahydrofuryl)-5-fluorouracil/uracil ( 1:4 ) ( UFT ) . The control group received the st and ard regimen only . MAIN OUTCOME MEASURES Five year survival and patterns of recurrence in three groups : no lymph node metastases , 1 - 9 , and 10 or more . RESULTS Only in the group with 1 - 9 lymph node metastases was there an appreciable but not significant difference in 5 year survival : 66 % compared with 44 % ( p = 0.084 ) . The mean disease free survival for patients with peritoneal metastases was 30 months in the CHPP group compared with 23 months among the controls . CONCLUSION CHPP improved prognosis in patients with T3 gastric cancer who had only 1 - 9 metastatic lymph nodes BACKGROUND Promising findings obtained using a weekly regimen of 5-fluorouracil ( 5-FU ) , epidoxorubicin , leucovorin ( LV ) , and cisplatin ( PELFw ) to treat locally advanced and metastatic gastric cancer prompted the Italian Group for the Study of Digestive Tract Cancer ( GISCAD ) to investigate the efficacy of this regimen as adjuvant treatment for high-risk radically resected gastric cancer patients . METHODS From January 1998 to January 2003 , 400 gastric cancer patients at high risk for recurrence including patients with serosal invasion ( stage pT3 N0 ) and /or lymph node metastasis ( stage pT2 or pT3 N1 , N2 , or N3 ) , were enrolled in a trial of adjuvant chemotherapies ; 201 patients were r and omly assigned to receive the  PELFw regimen , consisting of eight weekly administrations of cisplatin ( 40 mg/m2 ) , LV ( 250 mg/m2 ) , epidoxorubicin ( 35 mg/m2 ) , 5-FU ( 500 mg/m2 ) , and glutathione ( 1.5 g/m2 ) with the support of filgrastim , and 196 patients were assigned to a regimen consisting of six monthly administrations of a 5-day course of 5-FU ( 375 mg/m2 daily ) and LV ( 20 mg/m2 daily , 5-FU/LV ) . Disease-free and overall survival were estimated and compared between arms using hazard ratios ( HRs ) and Kaplan-Meier estimates . All statistical tests were two-sided . RESULTS The 5-year survival rates were 52 % in the PELFw arm and 50 % in the 5-FU/LV arm . Compared with the 5-FU/LV regimen , the PELFw regimen did not reduce the risk of death ( HR = 0.95 , 95 % confidence interval [ CI ] = 0.70 to 1.29 ) or relapse ( HR = 0.98 , 95 % CI = 0.75 to 1.29 ) . Less than 10 % of patients in either arm experienced a grade 3 or 4 toxic episode . Neutropenia ( occurring more often in the PELFw arm ) and diarrhea and mucositis ( more prevalent in the 5-FU/LV arm ) were the most common serious side effects . Nevertheless , only 19 patients ( 9.4 % ) completed the treatment in the PELFw arm and 85 ( 43 % ) patients completed the treatment in the 5-FU/LV arm . CONCLUSIONS Our study found no benefit from an intensive weekly chemotherapy in gastric cancer . The extent of toxicity experienced by the patients in the adjuvant setting suggests that , in gastric cancer , chemotherapy may be more safely administered preoperatively Purpose : This phase II r and omised trial was design ed to evaluate the therapeutic efficacy and feasibility of radio frequency regional hyperthermia in combination with chemotherapy for patients with advanced non-small lung cancer ( NSCLC ) . Methods : Eighty patients with pathologically proven advanced NSCLC , were enrolled and divided into two groups . Group A patients were treated by radio frequency regional hyperthermia in combination with the regimen of gemcitabine and cisplatin ( GP ) . Group B patients were treated with the GP regimen alone . Results : In group A , one patient achieved a complete response ( CR ) , 18 achieved a partial response ( PR ) , 18 achieved a stable disease and three experienced a progression of the disease . Thirty-three patients had a positive Clinical Benefit Response ( CBR ) . In group B , no patient achieved CR , 17 achieved PR , 19 achieved a stable disease and four experienced a progression of the disease . Nineteen patients had a positive CBR . Significant differences between the two groups were observed for the CBR ( P < 0.05 ) , but not for RR . Major toxicities included bone marrow depression , nausea , vomiting , without significant differences between the two groups ( P > 0.05 ) . Conclusions : Radio-frequency regional hyperthermia in combination with chemotherapy ( GP ) is a safe , well tolerated , and effective therapeutic modality for patients with advanced NSCLC . The addition of hyperthermia improved quality of life From 1988 to 1990 , 53 patients with squamous cell carcinoma of the thoracic oesophagus underwent subtotal oesophagectomy after either preoperative hyperthermo-chemoradiotherapy ( HCR therapy ) or chemoradiotherapy without hyperthermia ( CR therapy )  , in a prospect i ve r and omized trial carried out to examine the effects of hyperthermia given preoperatively . The two groups ( 27 patients given HCR therapy and 26 given CR therapy ) were found to be comparable with regard to prognostic factors of age , site of carcinoma , TNM stage , etc . Following preoperative evaluation by an upper GI series and endoscopy , a subtotal oesophagectomy was done for all 53 patients . All the resected specimens , including the lymph nodes , were histopathologically examined , and the effects of preoperative treatment were evaluated by findings in the upper GI series and endoscopy , as well as based on the histopathology of the excised tissues . There were no viable cancer cells in the resected specimens of seven patients in the HCR therapy group ( 26.9 % ) and of two patients in the CR therapy group ( 7.7 % ) . In addition , no hyperthermia complications were observed . The study suggests that preoperative HCR therapy may be a more beneficial therapy than preoperative CR therapy in patients with squamous cell carcinoma of the oesophagus who undergo a subtotal oesophagectomy BACKGROUND Surgical resection of adenocarcinoma of the stomach is curative in less than 40 percent of cases . We investigated the effect of surgery plus postoperative ( adjuvant ) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction . METHODS A total of 556 patients with resected adenocarcinoma of the stomach or gastroesophageal junction were r and omly assigned to surgery plus postoperative chemoradiotherapy or surgery alone . The adjuvant treatment consisted of 425 mg of fluorouracil per square meter of body-surface area per day , plus 20 mg of leucovorin per square meter per day , for five days , followed by 4500 cGy of radiation at 180 cGy per day , given five days per week for five weeks , with modified doses of fluorouracil and leucovorin on the first four and the last three days of radiotherapy . One month after the completion of radiotherapy , two five-day cycles of fluorouracil ( 425 mg per square meter per day ) plus leucovorin ( 20 mg per square meter per day ) were given one month apart . RESULTS The median overall survival in the surgery-only group was 27 months , as compared with 36 months in the chemoradiotherapy group ; the hazard ratio for death was 1.35 ( 95 percent confidence interval , 1.09 to 1.66 ; P=0.005 ) . The hazard ratio for relapse was 1.52 ( 95 percent confidence interval , 1.23 to 1.86 ; P<0.001 ) . Three patients ( 1 percent ) died from toxic effects of the chemoradiotherapy ; grade 3 toxic effects occurred in 41 percent of the patients in the chemoradiotherapy group , and grade 4 toxic effects occurred in 32 percent . CONCLUSIONS Postoperative chemoradiotherapy should be considered for all patients at high risk for recurrence of adenocarcinoma of the stomach or gastroesophageal junction who have undergone curative resection Purpose : The aim of this report was to determine the impact of hyperthermia ( HT ) on preoperative radiochemotherapy for locally advanced rectal cancer . Material s and methods : Between 1996 and 2007 , 235 patients with locally advanced rectal cancer were treated with concurrent preoperative radiochemotherapy with or without HT . The total dose of radiotherapy was 39.6 Gy for 109 patients ( group A ) and 45 Gy for 126 patients ( group B ) . Two or three cycles of chemotherapy were administered . Hyperthermia was given immediately after radiotherapy . Results : In the HT subgroup of group A , more patients achieved down-staging of T stage when compared to the non-HT subgroup ( 57.9 % versus 38 % , p = 0.047 ) . For the cN+ subgroup of all patients , the number of patients with ypN+ were significantly less in the HT subgroup ( 25 % versus 50 % , p = 0.022 ) . In group A , HT appeared to reduce distant metastasis , increase disease-free survival , and improve overall survival . Conclusions : HT seemed to increase the response of both primary tumour and lymph nodes to preoperative radiochemotherapy in patients with locally advanced rectal cancer . The relationship between increased response by HT and survival should be confirmed by a large prospect i ve r and omised trial BACKGROUND / AIMS Although the most frequent cause of death after curative resection of advanced gastric cancer is peritoneal recurrence , there was no effective therapy for the prevention of peritoneal recurrence . This r and omized trial sought to determine whether intraoperative chemohyperthermic peritoneal perfusion could eliminate microscopic residual disease and thereby improve survival of patients with advanced gastric cancer . METHODOLOGY One-hundred and thirty-nine patients with T2 - 4 gastric cancer underwent curative gastrectomy with extended lymphadenectomy .  These patients were r and omly allocated into the following three groups . Patients in the CHPP group received surgery + chemohyperthermic peritoneal perfusion , and those in the CNPP group underwent surgery + chemonormothermic peritoneal perfusion . The third group was surgery alone group . In the CHPP and CNPP groups , peritoneal cavity was perfused with 6 - 8 liters of heated saline at , respectively , 42 - 43 degrees C and 37 degrees C with 30 mg of mitomycin C and 300 mg of cisplatin by a extracorporeal circulation machine . RESULTS Major operative complication occurred in 19 % ( 9/48 ) , 14 % ( 6/44 ) and 19 % ( 9/47 ) of the CHPP , CNPP and surgery alone group , respectively . Complication which uniquely developed after chemohyperthermic peritoneal perfusion was bowel perforation . Mortality rates of each group were 4 % ( 2/48 ) , 0 % ( 0/44 ) and 4 % ( 2/47 ) in the CHPP , CNPP and surgery alone group , respectively . Overall 5-year survival rates of CHPP , CNPP and surgery alone groups were 61 % , 43 % and 42 % , respectively . In a subset analysis , patients with gastric cancer having serosal invasion or lymph node metastasis have shown a statistically significant improvement in survival when treated with chemohyperthermic peritoneal perfusion . However , chemonormothermic peritoneal perfusion had no survival benefit . By analyzing with Cox proportional hazard model , chemohyperthermic peritoneal perfusion emerged as an independent prognostic factor for good survival . Surgery alone had three-fold higher risk of death than chemohyperthermic peritoneal perfusion . CONCLUSIONS Chemohyperthermic peritoneal perfusion had an efficiency for the prophylaxis of recurrence after curative resection of advanced gastric cancer , and is indicated for patients with tumor infiltrating beyond serosal layer and node positive tumor Purpose : To compare the local tumour control , survival , and acute mucous toxicity of nasopharyngeal cancer ( NPC ) patients treated with conventional radiotherapy ( RT ) combined with intracavity hyperthermia versus conventional RT alone . Methods and material s : Previously untreated NPC patients were assigned r and omly into the conventional RT group and the hyperthermia group . In addition to curative RT , hyperthermia group patients received intracavity hyperthermia before or after RT ; T90 was 42.5 ° –43 ° C for 50 min twice a week for 7 weeks . Results : From August 2001 to July 2006 , 180 eligible patients with NPC were enrolled in this study .  The complete response ( CR ) rate in the two arms ( RT plus hyperthermia versus conventional RT ) was 95.6 % and 81.1 % , respectively ( p = 0.003 , χ2 test ) . CR rates for T2 and T3 patients in the hyperthermia group were 97.1 % and 96.9 % , respectively , while in the conventional RT group they were 79.5 % and 76.7 % , respectively . The difference between the two groups was statistically significant ( p = 0.03 and p = 0.024 , respectively ) . The 5-year local control rate was 91.1 % and 78.9 % for the two arms , respectively ( p = 0.022 ) . Oral mucous toxicity in both arms was comparable . The 5-year PFS and 5-year OS rate for the hyperthermia arm vs. the conventional arm were 72.7 % versus 63.1 % ( p = 0.039 ) and 78.2 % versus 70.3 % ( p = 0.14 ) , respectively . Conclusions : Conventional RT treatment followed by intracavity hyperthermia was well tolerated by the NPC patients . The addition of hyperthermia improved the local tumour control , and our results indicated a positive impact on PFS of NPC patients Background . Continuous hyperthermic peritoneal perfusion ( CHPP ) with a solution that contained 10 μg/ml mitomycin C was devised initially as a method for intraperitoneal thermochemotherapy . The authors conducted a r and omized clinical trial to evaluate the efficacy of  CHPP  as a prophylactic treatment for prevention of peritoneal recurrence of gastric cancer with serosal invasion We performed continuous hyperthermic peritoneal perfusion ( CHPP ) or continuous normothermic peritoneal perfusion ( CNPP ) combined with cisplatin ( CDDP ) 300 mg/kg and mitomycin C ( MMC ) 30 mg/kg in an attempt to prevent peritoneal recurrence after surgery for gastric cancer . Twenty-two patients were treated with perfusion  using about 10 liters of saline heated to 41 ° to 42 ° C ( CHPP group ) ;  18 patients were treated with saline heated to 37 ° to 38 ° C ( CNPP group ) ; and 18 patients underwent only gastric surgery without perfusion ( control group ) in a r and omized control study . There were two deaths ( 9 % ) due to peritoneal recurrence in the CHPP group , four ( 22 % ) in the CNPP group , and four ( 22 % ) in the control group . The 1- , 2- , and 3-year survival rates were 95 % , 89 % , and 68 % , in the CHPP group ; 81 % , 75 % , and 51 % , in the CNPP group ; and 43 % , 23 % , and 23 % , in the control group , respectively . There was a significant difference between the three survival curves by the log-rank test ( p<0.01 ) . This difference showed that CNPP and CHPP are both effective procedures for preventing peritoneal recurrence . The maximum concentrations in the perfusate of total and free CDDP with 300 mg administration were 12.2 and 10.1 μg/ml , respectively , at the end of the perfusion , and the maximum concentrations of total and free CDDP in plasma were 2.1 and 1.0 μg/ml , respectively . The maximum concentrations of MMC in perfusate and plasma with 30 mg administration were 1.00 and 0.05 μg/ml , respectively , which are intraperitoneally cytotoxic but systemically safe concentrations . RésuméNous mettons en place une perfusion intrapéritonéale hyper ( PPHC ) ou isothermique continue ( PPNC ) , associée à une chimiothérapie combinée ( cisplatine ( CDDP ) à la posologie de 300 mg/Kg et mitomycine C ( MMC ) à la posologie de 30 mg/Kg ) dans le but de prévenir les récidives péritonéales après chirurgie pour cancer gastrique . Dans une étude r and omisée , 22 patients ont été traités par perfusions péritonéale avec 10 liters de sérum physiologique chauffé à 41–42 ° C ( PPHC ) , 18 ont été traités avec du sérum à 37 ° C ( PPNC ) et 18 ont été opérés de leur cancer gastrique  sans perfusion postopératoire ( groupe contrôle ( 22 % ) ) . Les survies à 1 , 2 et 3 ans étaient de 95 , 89 et 68 % , respectivement dans le groupe PPHC , de 81 , 75 et 51 % dans le groupe PPNC et de 43 , 23 et 23 % dans le groupe contrôle . Les trois courbes de survie différaient de façon significative ( logrank p<0.01 ) . Ces différences montrent que non seulement la perfusion intrapéritonéale associée à la chimiothérapie mais aussi l'hyperthermie intrapéritonéale sont efficaces pour prévenir la récidive péritonéale . après résection gastrique pour cancer . Les concentrations maximales globales et isolées de CDDP  étaient de 12.2 et de 10.1 μg/ml à la fin de la perfusion . Les concentrations plasmatiques maximales de MMC globales et isolées étaient de 1.00 et de 0.05 μg/ml . , respectivement . Ces résultats cliniques favorables démontrent que les concentrations obtenues ainsi ne sont pas nocives . ResumenEn pacientes sometidos a cirugía por cáncer gástrico hemos realizado perfusión peritoneal hipertérmica continua ( PPHC ) o perfusión peritoneal normotérmica continua ( PPNC ) combinada con cisplatino ( CCDP ) en dosis de 300 mg/cuerpo y mitomicina C ( MMC ) en dosis de 30 mg/cuerpo con miras a prevenir la recurrencia peritoneal . Veintidós pacientes fueron tratados con perfusión de alrededor de 10 litros de solución salina calentada a 41–42 ° C ( grupo PPHC ) ; 18 pacientes fueron tratados con solución salina calentada a 37–38 ° C ( grupo PPNC ) ; y 18 pacientes fueron sometidos a cirugía gástrica solamente , sin perfusión , los cuales constituyeron el grupo de control . El estudio fue r and omizado . Las muertes por recurrencias peritoneales fueron dos ( 9 % ) en el grupo PPHC , cuatro ( 22 % ) en el grupo PPNC y cuatro ( 22 % ) en el grupo control . Las tasas de sobrevida a uno , dos y tres años fueron 95 % , 89 % y 68 % en el grupo PPHC ; 81 % , 75 % y 51 % en el grupo PPNC ; y 43 % , 23 % y 23 % en grupo control , respectivamente . Se encontró una diferencia significativa en las tres curvas de sobrevida en la prueba de log-rank ( p<0.01 ) . La significativa diferencia hallada entre las tres curvas de sobrevida demuestran que , no sólo la perfusión intraperitoneal combinada con quimioterapia ( PPNC ) sino también la hipertermia intraperitoneal ( PPHC ) , son procedimientos efectivos para la prevención de la recurrencia peritoneal . Las concentraciones máximas del CCDP total y libre en el líquido de perfusión en el régimen de 300 mg fue 12.2 y 10.1 μg/ml al final de la perfusión . Las máximas concentraciones plasmáticas de CDDP total y libre fueron 2.1 y 1.0 μg/ml al final de la perfusión . Las concentraciones máximas de MMC en el líquido de perfusión y en el plasma en regímenes por debajo de 30 mg fueron 1.0 y 0.05 μg/ml . Tales result ados demuestran concentraciones intraperitoneales citotóxicas pero sistémicamente seguras The majority of advanced gastric carcinoma patients with serosal invasion die of peritoneal recurrence , even when a curative gastrectomy is performed , because peritoneal recurrence occurs due to intraperitoneal free tumor cells that detach from the serosal‐invaded focus . In an attempt to prevent peritoneal recurrence , intraperitoneal hyperthermic chemoperfusion ( IHCP ) treatment was combined with aggressive surgery BACKGROUND A regimen of epirubicin , cisplatin , and infused fluorouracil ( ECF ) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma . We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer . METHODS We r and omly assigned patients with resectable adenocarcinoma of the stomach , esophagogastric junction , or lower esophagus to either perioperative chemotherapy and surgery ( 250 patients ) or surgery alone ( 253 patients ) . Chemotherapy consisted of three preoperative and three postoperative cycles of intravenous epirubicin ( 50 mg per square meter of body-surface area ) and cisplatin ( 60 mg per square meter ) on day 1 , and a continuous intravenous infusion of fluorouracil ( 200 mg per square meter per day ) for 21 days . The primary end point was overall survival . RESULTS  ECF-related adverse effects were similar to those previously reported among patients with advanced gastric cancer .  Rates of postoperative complications were similar in the perioperative-chemotherapy group and the surgery group ( 46 percent and 45 percent , respectively ) , as were the numbers of deaths within 30 days after surgery . The resected tumors were significantly smaller and less advanced in the perioperative-chemotherapy group . With a median follow-up of four years , 149 patients in the perioperative-chemotherapy group and 170 in the surgery group had died . As compared with the surgery group , the perioperative-chemotherapy group had a higher likelihood of overall survival ( hazard ratio for death , 0.75 ; 95 percent confidence interval , 0.60 to 0.93 ; P=0.009 ; five-year survival rate , 36 percent vs. 23 percent ) and of progression-free survival ( hazard ratio for progression , 0.66 ; 95 percent confidence interval , 0.53 to 0.81 ; P<0.001 ) . CONCLUSIONS In patients with operable gastric or lower esophageal adenocarcinomas , a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival . ( Current Controlled Trials number , IS RCT N93793971 [ controlled-trials.com ] . ) OBJECTIVE To explore the effect of hyperthermic intraoperative intraperitoneal chemotherapy ( HIIC ) on the  postoperative metastatic rate and survival rate of advanced gastric cancer ( AGC ) . METHODS In HIIC group , patients received HIIC ( mitomycin C 30 mg and cisplatin 100 mg were added into 2000 ml distilled water , heated to 42 approximately 45 degrees C , perfused to abdominal cavity for 30 min and then sucked ) and intravenous chemotherapy after operation ( 5- FU 10 approximately 15 mg/kg , mitomycin C 0.1 approximately 0.15 mg/kg , adriamycin 0.5 approximately 1 mg/kg i.v drip , once a week for 2 approximately 3 weeks ) . In control group , patients received intravenous chemotherapy only . The postoperative metastatic rate and survival rate ( 1- , 3- and 5- year ) of patients were compared between 92 cases of AGC undergone HIIC and 120 cases of AGC without HIIC ( control group ) . RESULTS The peritoneal recurrence rates after operations occurred within two years were 14.1 % and 37.5 % in HIIC group and control group respectively ( P < 0.01 ) . The 1- , 3- , and 5- year survival rates in HIIC group were 98.9 % , 68.5 % , and 52.2 % and in control group 95.0 % , 56.7 % and 37.5 % respectively . The 3- , and 5- year survival rates were significantly different between the two the groups ( P < 0.05 ) . CONCLUSION HIIC can kill isolated intraperitoneal cancer cells , reduce peritoneal recurrence rate after operations , raise significantly survival rate of patient , and improve the prognosis of AGC
Background : Adjuvant intraoperative hyperthermic intraperitoneal chemotherapy ( IHIC ) is a therapy which combines thermotherapy and intraperitoneal chemotherapy .
It is theoretically powerful for patients with advanced gastric cancer ( AGC ) , but is there evident advantage in clinical practice ?
We need evidence to guide our decision-making .
Objectives : Meta- analysis was performed to assess the effectiveness and safety of adjuvant intraoperative hyperthermic intraperitoneal chemotherapy ( IHIC ) for patients with resectable locally advanced gastric cancer , and to provide the reference for clinical practice and study .